Virax Biolabs CEO James Foster Provides Shareholder Update on Fiscal 2026 Financials, Fosun Diagnostics Agreement, and Nasdaq Compliance
Virax Biolabs reported $6.4 million in cash as of March 31, 2026, with a total asset value of $8.3 million following its fiscal year-end report filed on July 2, 2026. The company also announced a commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets and completed an investment option exercise that raised approximately $3.3 million in gross proceeds.
